Celltrion History, CEO, Future, Stock Price Analysis

Celltrion is a comprehensive biotechnology company in South Korea.

1. Celltrion History

Celltrion History, Celltrion is a South Korean comprehensive biotechnology company founded on December 2, 1999. Starting with the pharmaceutical consignment production (CMO) business in 2002, Celltrion has grown into a global leader in the field of biosimilars by developing, clinical, and licensing a number of biosimilars in 2009. Celltrion's representative products include infliximab biosimilar Remsima, which is used to treat various diseases such as rheumatoid arthritis, psoriasis, and ulcerative colitis, Rituximab biosimilar Truxima, psoriasis, and ankylosing spondylitis. Celltrion's biosimilar products are sold in more than 100 countries around the world, including Europe, the United States, and Japan, and continue to invest in R&D to strengthen its competitiveness in the global biopharmaceutical market. Celltrion is currently developing more than 10 new biopharmaceutical drugs. Celltrion was listed on the KOSPI in April 2018, with a market capitalization of about 30 trillion won as of 2022, ranking it among the top 10 listed companies in Korea. Celltrion is recognized as a company that develops with the local community through various activities such as job creation and social contribution. Celltrion will continue to grow into a global biotechnology company by developing innovative products in various fields such as biosimilars, biosimilars, and vaccines.

2. CEO of Celltrion

Celltrion CEO, Celltrion's current CEO is Seo Jung-jin. Seo Jung-jin was born in 1958 and majored in mathematics at Seoul National University. He joined Samsung Electronics in 1983 and worked as a semiconductor researcher before establishing Celltrion in 1999. Seo Jung-jin is the one who has grown Celltrion into a global leader in biosimilar. He grew Celltrion into a global company with bold investments in biosimilar development and commercialization and innovative management. Seo Jung-jin was also selected as the Young Global Leaders of the World Economic Forum (WEF) Annual Meeting (Davos Forum) as the CEO of Korea's only biotechnology company in 2018. Seo Jung-jin aims to contribute to the health of mankind through innovation and global expansion in the fields of biosimilars and biosimilars.

3. Celltrion Future

Celltrion Future, Celltrion is a company specializing in developing and manufacturing antibody biosimilars. Since its establishment in 2001, it has been successful in the global market by launching a number of biosimilar products, including Remsima, Truxima, and Herzuma. Celltrion's future is bright. The biosimilar market is growing rapidly, and Celltrion is in a position to expand its market share. Celltrion is also actively investing in the development of new drugs. Celltrion's new drug pipeline includes various pipelines such as ADC anticancer drugs, CAR-T treatments, and immuno-cancer drugs. Some of Celltrion's new drug pipelines have entered the clinical stage and are paying off. Celltrion is a company that can catch two rabbits, biosimilar and new drug development. Celltrion is expected to continue its growth in the future.

4. Celltrion Stock Price Analysis

Shares of Celltrion have risen about 30% since January 2022. The main factors behind the rise in stock prices are growth in the biosimilar market and expectations for new drug development. The biosimilar market is growing at an average annual rate of more than 10%, and Celltrion is the global leader in the biosimilar market. Celltrion has been successful in the global market by launching a number of biosimilar products, including Remsima, Truxima, and Herzuma. Celltrion is also actively investing in the development of new drugs. Celltrion's new drug pipeline includes various pipelines such as ADC anticancer drugs, CAR-T treatments, and immuno-cancer drugs. Some of Celltrion's new drug pipelines have entered the clinical stage and are paying off. But Celltrion's shares have fallen about 10% since January 2023. The main factors behind the fall in stock prices are a slowdown in the global economy and intensifying competition in the biosimilar market. The slowdown in the global economy may reduce demand for biosimilar products, a major customer of Celltrion. In addition, competition in the biosimilar market is intensifying, and Celltrion may intensify competition with multinational pharmaceutical companies. Overall, Celltrion's stock price is supported by growth in the biosimilar market and expectations for new drug development. But a slowdown in the global economy and intensifying competition in the biosimilar market could put downward pressure on Celltrion's stock price.

CELLTRION, LOGO